# KEYMAKER-U04 (NCT05845814)

> A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

No report yet. It can be ordered.

- Drugs tested: MK-4280A plus enfortumab vedotin; MK-7684A plus enfortumab vedotin
- Indication: first-line metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05845814
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Metastatic Urothelial Carcinoma; Urothelial Neoplasms
- Interventions: Coformulated favezelimab/pembrolizumab; Coformulated vibostolimab/pembrolizumab; EV; Pembrolizumab
- Enrollment: 390
- Primary outcome: Part 1: Objective Response Rate (ORR)
- Primary outcome: Part 1: Percentage of Participants experiencing an Adverse Event (AE)
- Primary outcome: Part 1: Percentage of Participants who Discontinue study interventions due to an AE
- Primary outcome: Part 1: Percentage of Participants with Dose-limiting toxicities (DLT)
- Primary outcome: Part 2: Progression Free Survival (PFS)

## Indexed commentary on KEYMAKER-U04 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keymaker-u04-nct05845814

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05845814", "email": "<work email>"}; the inbox owner confirms by the emailed link.